A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)
Clinical trial NCT06144749 · COMPLETED
Trial details
- NCT number
- NCT06144749
- Sponsor
- Hillhurst Biopharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-15
- Primary completion
- 2026-06-30
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.